Celltrion

Celltrion’s Yuflyma secures FDA interchangeability designation with Humira in US Korea Biomedical Review08:09FDA Pharma Inflammatory Bowel Disease

Celltrion adalimumab biosimilar granted interchangeability designation JD Supra17:20FDA Pharma Inflammatory Bowel Disease

Celltrion gets interchangeability approval for biosimilar of Humira in the U.S. Korea JoongAng Daily03:28Interchangeability Humira Biotechnology

Celltrion gets interchangeability approval for biosimilar of Humira in US The Korea Herald01:19Interchangeability Humira Biotechnology

Eye on pharma: Sandoz files antitrust suit; Yuflyma interchangeability; Costco’s ustekinumab pick Center for Biosimilars17:14FDA Amgen Patent Law

Celltrion scores Australian approval for 3 biosimilars in 2 weeks Korea Biomedical Review06:27Australia South Pacific

Celltrion wins 3 biosimilar approvals in Australia, eyes Oceania growth The Korea Herald09:11Australia South Pacific

Celltrion's Stelara biosimilar secures formulary listing with major US Pbm Korea Biomedical Review03:40Stelara

March Stelara® biosimilar launches: Fresenius kabi’s otulfi® and Celltrion’s Steqeyma™ JD Supra05:16Stelara

Spotlight on: Herceptin® (trastuzumab) / ogivri® (trastuzumab-dkst) / herzuma® (trastuzumab-pkrb) / ontruzant®… JD Supra16:35Pfizer Samsung Pharma

Spotlight on: Rituxan® (rituximab) / truxima® (rituximab-abbs) / ruxience® (rituximab-pvvr) / riabni™ (rituximab-arrx)… JD Supra22:14Pfizer Samsung Pharma

Celltrion chairman, 2 affiliates to purchase 200 bln-won Celltrion stocks Yonhap News Agency01:10Biotechnology

Celltrion chairman, two affiliates to buy back $135 million in shares Korea JoongAng Daily10:14Biotechnology

Latest News

Yesterday

Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick Center for Biosimilars17:14 22-Apr-25

Celltrion to unveil next-generation antibody drug technologies at AACR 2025 Korea Biomedical Review05:32 22-Apr-25

In the last 7 days

Celltrion Adalimumab Biosimilar Granted Interchangeability Designation JD Supra17:20 21-Apr-25

Spotlight On: Biosimilar Litigations - April 2025 JD Supra16:35 18-Apr-25

Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant®… JD Supra16:35 18-Apr-25

Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)… JD Supra22:14 17-Apr-25

FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma PMLiVE12:47 17-Apr-25

In the last month

U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's… PR Newswire (Press Release)01:59 15-Apr-25

Celltrion’s Yuflyma secures FDA interchangeability designation with Humira in US Korea Biomedical Review08:09 14-Apr-25

Celltrion gets interchangeability approval for biosimilar of Humira in the U.S. Korea JoongAng Daily03:28 14-Apr-25

Celltrion gets interchangeability approval for biosimilar of Humira in US The Korea Herald01:19 14-Apr-25

Celltrion wins 3 biosimilar approvals in Australia, eyes Oceania growth The Korea Herald09:11 10-Apr-25

Celltrion scores Australian approval for 3 biosimilars in 2 weeks Korea Biomedical Review06:27 10-Apr-25

Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear Simply Wall St03:47 10-Apr-25

Celltrion chairman, 2 affiliates to purchase 200 bln-won Celltrion stocks Yonhap News Agency01:10 10-Apr-25

Celltrion chairman, two affiliates to buy back $135 million in shares Korea JoongAng Daily10:14 9-Apr-25

Celltrion CEO’s blueprint: ADCs, multispecific antibodies Korea Biomedical Review02:55 9-Apr-25

With Korea nod for Prolia biosimilar, Samsung Bioepis moves in on Celltrion’s lead Korea Biomedical Review01:47 8-Apr-25

Celltrion's Stelara biosimilar secures formulary listing with major US PBM Korea Biomedical Review03:40 7-Apr-25

Celltrion boosts global push for Yuflyma with phase 3 data on Humira Interchangeability Korea Biomedical Review07:04 4-Apr-25

March Stelara® Biosimilar Launches: Fresenius Kabi’s Otulfi® and Celltrion’s Steqeyma™ JD Supra05:16 3-Apr-25

Celltrion expands startup hunt overseas through Seoul Biohub open innovation deal Korea Biomedical Review02:26 1-Apr-25

Celltrion wins CHMP backing for autoinjector form of Omlyclo Korea Biomedical Review06:51 31-Mar-25

Celltrion’s Vegzelma generates $56m in US, eyes growth in Europe, Latin America The Korea Herald04:47 28-Mar-25

Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April … Business Wire (Press Release)05:51 27-Mar-25

Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program PR Newswire (Press Release)05:31 27-Mar-25

Celltrion Wins Costco Formulary Listing for its Recently Launched Ustekinumab JD Supra18:59 25-Mar-25

Celltrion Chairman Seo Jung-jin reappointed as executive director, company expects visible growth in 2025 Korea Biomedical Review04:21 25-Mar-25

Celltrion’s Stelara biosimilar wins Costco formulary listing Korea Biomedical Review06:24 24-Mar-25

LigaChem Bio takes control of UK’s Iksuda, while Celltrion charts independent ADC path Korea Biomedical Review02:02 24-Mar-25

view more headlines

22 Apr 17:14

About our Celltrion news

Latest news on Celltrion, a biopharmaceutical company headquartered in Incheon, South Korea.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.